On October 20, 2025, Clearmind Medicine Inc. announced the publication of a U.S. patent application with the United States Patent and Trademark Office for a novel combination therapy of 5‑methoxy‑2‑aminoindane (MEAI) and N‑acylethanolamines, such as palmitoylethanolamide (PEA). The filing addresses binge‑behavior disorders, including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct.
The application builds on Clearmind’s existing collaboration with SciSparc Ltd. and expands the company’s intellectual‑property portfolio, which already includes 13 patents related to MEAI‑PEA combinations for conditions such as alcohol use disorder, cocaine addiction, obesity, weight loss, and depression. The therapy leverages MEAI’s neuroplastic properties to reduce impulsivity and reward‑seeking behavior, while PEA provides synergistic pharmacological benefits, potentially offering a safer and more effective treatment for substance use disorders and addictions.
CEO Dr. Adi Zuloff‑Shani said the publication “represents yet another advancement in our mission to pioneer safe and effective, next‑generation treatments for binge behaviors.” The filing strengthens Clearmind’s competitive position in the emerging psychedelic therapeutics market and lays the groundwork for future clinical development of the combination therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.